Form 497VPU VARIABLE ANNUITY ACCOUNT
Tweet
Share
E-mail| EliteDesigns®
Variable Annuity EliteDesigns®
II Variable Annuity SecureDesigns Variable Annuity |
|
| Issued By: |
|
| First Security Benefit Life Insurance
and Annuity Company of New York
121 State Street
Albany, NY 12207 |
|
Supplement Dated November 27, 2024
To the Summary and Statutory Prospectuses
Dated May 1, 2024
To the Summary and Statutory Prospectuses
Dated May 1, 2024
Effective immediately, the second paragraph of “Appendix A – Underlying Funds Available Under the Contract” is deleted in its entirety and replaced with the following:
The current expenses and
performance information below reflect the fees and expenses of the Underlying Funds, but do not reflect the other fees and expenses that your Contract may charge. Expenses would be
higher and performance would be lower if these other charges were included. Each Underlying Fund’s past performance is not necessarily an indication of future performance. Updated performance information is available online at
https://www.fsbl.com/performance.
Please Retain This Supplement For Future Reference
FS-10002-32 2024/11/27
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and
- New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer
- Frontier Medicines Presents Promising Anti-Tumor Activity from Phase 1/2 PROSPER Trial of FMC-376 in a Highly Resistant Patient Population of KRAS G12C-Mutant NSCLC at ESMO 2026
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
